Clinical trial NCT04122118: Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor
Official title: Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malignant Solid Neoplasm
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2019-10-10
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

Detailed description: PRIMARY OBJECTIVE:

I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.

SECONDARY OBJECTIVE:

I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.

EXPLORATORY OBJECTIVE:

I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.

OUTLINE:

PHASE I: Patients' medical records are reviewed.

PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

After completion of study, patients are followed up periodically.

Eligibility criteria: Inclusion Criteria:

* Solid tumor diagnosis
* Starting day 1 of new antineoplastic infusion
* English speaking (and/or English-speaking primary caregiver/proxy)

Exclusion Criteria:

* Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
* Severe cognitive impairment including dementia with inability to consent to the study

Primary outcomes:
measure: Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
timeFrame: Up to 1 year
measure: Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)
timeFrame: Up to 1 year
Secondary outcomes:
measure: Patient and provider satisfaction with the pharmacist-led education
timeFrame: Up to 1 year
Other outcomes:
measure: Estimate of Cost avoidance utilizing pharmacy services
timeFrame: Up to 1 year
Locations:
city: Philadelphia
country: United States
facility: Sidney Kimmel Cancer Center at Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
name: Gloria Espinosa, PharmD
role: PRINCIPAL_INVESTIGATOR
References: